ReNEW: A Phase 3, Double-Masked, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects Who Have Dry Age-Related Macular Degeneration (Dry AMD)

The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in subjects who receive a daily dose of elamipretide compared with those who receive a look-alike substance that contains no active drug, and what is the safety and tolerability of elamipretide daily subcutaneous injections. Participants will receive either once daily subcutaneous doses of 40mg elamipretide or placebo and the two treatment groups will be compared.

Start Date30 May 2024

Sponsor / Collaborator

Stealth BioTherapeutics, Inc.

EUCTR2021-003907-16-NL / Unknown statusPhase 3

A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects with Primary Mitochondrial Disease Resulting from Pathogenic Nuclear DNA Mutations (nPMD)

Start Date21 Jul 2022

Sponsor / Collaborator

Stealth BioTherapeutics, Inc.

NCT05162768 / Active, not recruitingPhase 3

A Phase 3 Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Subjects With Primary Mitochondrial Disease Resulting From Pathogenic Nuclear DNA Mutations (nPMD) NuPower

SPIMD-301 is a 48-week, randomized, double-blind, parallel-group, placebo-controlled trial to assess efficacy and safety of single daily subcutaneous (SC) administration of elamipretide as a treatment for subjects with primary mitochondrial myopathy associated with nuclear DNA mutations (nPMD).

Start Date29 Apr 2022

Sponsor / Collaborator

Stealth BioTherapeutics, Inc.

100 Clinical Results associated with Elamipretide Hydrochloride

100 Translational Medicine associated with Elamipretide Hydrochloride

100 Patents (Medical) associated with Elamipretide Hydrochloride

316

Literatures (Medical) associated with Elamipretide Hydrochloride

01 Dec 2024·Cellular and molecular life sciences : CMLS

Mitochondrial oxidative damage reprograms lipid metabolism of renal tubular epithelial cells in the diabetic kidney

Article

Author: Zhu, Guozhen ; Niu, Hiumin ; Li, Jing ; Wang, Lihua ; Wu, Wenjie ; Shi, Honghong ; Wan, Xing ; Ren, Xiayu ; Chen, Yiliang ; Li, Yafeng ; Tan, Enxue ; Hou, Yanjuan

Abstract:

The functional and structural changes in the proximal tubule play an important role in the occurrence and development of diabetic kidney disease (DKD). Diabetes-induced metabolic changes, including lipid metabolism reprogramming, are reported to lead to changes in the state of tubular epithelial cells (TECs), and among all the disturbances in metabolism, mitochondria serve as central regulators. Mitochondrial dysfunction, accompanied by increased production of mitochondrial reactive oxygen species (mtROS), is considered one of the primary factors causing diabetic tubular injury. Most studies have discussed how altered metabolic flux drives mitochondrial oxidative stress during DKD. In the present study, we focused on targeting mitochondrial damage as an upstream factor in metabolic abnormalities under diabetic conditions in TECs. Using SS31, a tetrapeptide that protects the mitochondrial cristae structure, we demonstrated that mitochondrial oxidative damage contributes to TEC injury and lipid peroxidation caused by lipid accumulation. Mitochondria protected using SS31 significantly reversed the decreased expression of key enzymes and regulators of fatty acid oxidation (FAO), but had no obvious effect on major glucose metabolic rate-limiting enzymes. Mitochondrial oxidative stress facilitated renal Sphingosine-1-phosphate (S1P) deposition and SS31 limited the elevated Acer1, S1pr1 and SPHK1 activity, and the decreased Spns2 expression. These data suggest a role of mitochondrial oxidative damage in unbalanced lipid metabolism, including lipid droplet (LD) formulation, lipid peroxidation, and impaired FAO and sphingolipid homeostasis in DKD. An in vitro study demonstrated that high glucose drove elevated expression of cytosolic phospholipase A2 (cPLA2), which, in turn, was responsible for the altered lipid metabolism, including LD generation and S1P accumulation, in HK-2 cells. A mitochondria-targeted antioxidant inhibited the activation of cPLA2f isoforms. Taken together, these findings identify mechanistic links between mitochondrial oxidative metabolism and reprogrammed lipid metabolism in diabetic TECs, and provide further evidence for the nephroprotective effects of SS31 via influencing metabolic pathways.

01 Mar 2024·Mitochondrion

Application research of novel peptide mitochondrial-targeted antioxidant SS-31 in mitigating mitochondrial dysfunction

Review

Author: Liu, Weixin ; Luo, Yunchang ; Li, Ninjing ; Zhang, Guohui ; He, Libing ; Zeng, Qin ; Han, Changli ; Zhao, Yuhong ; Du, Xinrong

Due to the pivotal role of mitochondria in the generation of adenosine triphosphate (ATP) and the regulation of cellular homeostasis, mitochondrial dysfunction may exert a profound impact on various physiological systems, potentially precipitating a spectrum of distinct diseases. Consequently, research pertaining to mitochondrial therapeutics has assumed increasing significance, warranting heightened scrutiny. In recent years, the field of mitochondrial therapy has witnessed noteworthy advancements, with active exploration into diverse pharmacological agents aimed at ameliorating mitochondrial function. Elamipretide (SS-31), a novel synthetic mitochondrial-targeted antioxidant, has emerged as a promising candidate with extensive therapeutic potential. Its notable attributes encompass the mitigation of oxidative stress, the suppression of inflammatory processes, the maintenance of mitochondrial dynamics, and the prevention of cellular apoptosis. As such, SS-31 may emerge as a viable choice for the treatment of mitochondrial dysfunction-related ailments in the foreseeable future. This article extensively expounds upon the superiority of SS-31 over natural antioxidants and traditional mitochondrial-targeted antioxidants, delves into its mechanisms of modulating mitochondrial function, and comprehensively summarizes its applications in alleviating mitochondrial dysfunction-associated disorders. Furthermore, we offer a comprehensive outlook on the expansive prospects of SS-31's future development and application.

01 Jan 2024·Acta biomaterialia

Platelet membrane-coated bio-nanoparticles of indocyanine green/elamipretide for NIR diagnosis and antioxidant therapy in acute kidney injury

Article

Author: Hu, Xiaojuan ; Fan, Weijiao ; Chen, Yang ; Yao, Shijie ; Yang, Xianghong ; Wu, Danping ; Cai, Yu ; Mou, Xiaozhou

Acute kidney injury (AKI) is a prevalent condition in critically ill patients that is often associated with significant morbidity and mortality. As the lack of effective early diagnosis methods often delays AKI treatment, there is currently no definitive clinical intervention available. In this study, we aimed to address these challenges by developing a nano-system called Platelet membranes-ICG-SS31-PLGA (PISP), which was designed to selectively target to the kidney site, taking advantage of the natural tendency of platelets to accumulate at sites of vascular injury. This approach allowed for the accumulation of PISP within the kidney as the disease progresses. By incorporating ICG, the in vivo distribution of PISP can be observed for NIR diagnosis of AKI. This non-invasive imaging technique holds great promise for early detection and monitoring of AKI. Furthermore, Elamipretide (SS31) acts as a mitochondria-targeted antioxidant that protects against mitochondrial damage and reduces oxidative stress, inflammation, and apoptosis. The combination of diagnostic and therapeutic capabilities within a single nano-system makes the PISP approach a valuable tool for addressing AKI. This intervention helps to prevent the deterioration of AKI and promotes the recovery. STATEMENT OF SIGNIFICANCE.

News (Medical) associated with Elamipretide Hydrochloride

05 Jun 2024

·www.prnewswire.com

Stealth BioTherapeutics Announces First Patient Enrolled in Global Phase 3 Clinical Program for Elamipretide in Patients with Dry Age-Related Macular Degeneration

NEEDHAM, Mass., June 5, 2024 /PRNewswire/ -- Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has enrolled and dosed its first patient in the ReNEW trial (NCT06373731) as part of its Phase 3 clinical program for elamipretide in patients with dry age-related macular degeneration (dry AMD). The program consists of the two Phase 3 trials, ReNEW and ReGAIN. Both trials will evaluate the efficacy, safety, and pharmacokinetics of daily subcutaneous injections of elamipretide in participants with dry AMD. The primary efficacy endpoint will measure the rate of change in the macular area of photoreceptor loss, assessed by spectral domain-optical coherence tomography (SD-OCT) and ellipsoid zone (EZ) mapping at week 48. "Enrolling the first patient in our Phase 3 program puts us one step closer to bringing a potential first-in-class, at-home treatment option to patients living with dry AMD," said Reenie McCarthy, Chief Executive Officer. "With multiple sites now active and able to enroll patients in the U.S., we are off to a great start and look forward to evaluating the efficacy and safety of elamipretide in patients with dry AMD in these pivotal Phase 3 trials." "There remains a tremendous need for new therapies with differentiated mechanisms of action to treat dry AMD, especially those that could be readily employed for the management of earlier stages of disease," said Charles Wykoff, MD, PhD from Retinal Consultants of Texas. "Elamipretide, a mitochondrial targeted therapy, can be self-administered by patients at home. It holds the potential to be a transformative approach to dry AMD management by targeting the bioenergetic imbalance implicated in the progressive loss of photoreceptors that defines AMD and leads to progressive visual decline." About ReNEW and ReGAIN ReNEW and ReGAIN are Phase 3 global clinical trials evaluating the efficacy and safety of once-daily subcutaneous injections of elamipretide in participants with dry AMD. The primary endpoint for the trials is the rate of change in the macular area of photoreceptor loss assessed by spectral domain-optical coherence tomography and ellipsoid zone mapping. In the ReNEW trial, 360 patients will be randomized 2:1 to either elamipretide or placebo for 96 weeks with the option for participants to enroll in the open-label extension trial, ReTAIN. About dry AMD AMD is the leading cause of irreversible blindness and is estimated by the Vision and Eye Health Surveillance System to affect 19.8 million Americans aged 40 and older (Rein 2022), with 85% to 90% of cases being dry AMD (Schultz 2021). Dry AMD is a progressive retinal disease in which the photoreceptors, which are specialized neurons found in the retina that convert light into electrical signals required for normal visual function, suffer progressive damage and death, leading to loss of vision. Mitochondrial dysfunction, which has been associated with aging, smoking, obesity, and cardiovascular health, is known to precede clinical symptoms of AMD and increase commensurate with AMD disease progression (Feher 2006; Karunadharma 2010; Terluk 2015). Photoreceptor loss can be quantified by measuring the thickness between the EZ and retinal pigment epithelium (i.e., EZ-RPE thickness). Loss of photoreceptors cells, or EZ attenuation, has been shown to precede and predict the loss of visual function and areas of geographic atrophy in dry AMD. About Stealth BioTherapeutics Stealth BioTherapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for age-related and rare genetic diseases involving mitochondrial dysfunction. The Company is initiating Phase 3 clinical trials of elamipretide, its lead investigational product candidate, in dry age-related macular degeneration. Elamipretide is also being tested in a fully enrolled Phase 3 clinical trial in primary mitochondrial myopathy, a rare skeletal myopathic disease, and is under review by the Food and Drug Administration for Barth syndrome, an ultra-rare cardioskeletal disease. The Company is developing its second-generation clinical-stage candidate, bevemipretide (SBT-272), for ophthalmic and neurological disease indications. The Company has a deep pipeline of novel mitochondria-targeted compounds under evaluation as therapeutic product candidates. Investor Contact Austin Murtagh Precision AQ [email protected] Media Contact Anna Stallmann Anna Stallmann Communications [email protected] SOURCE Stealth BioTherapeutics Inc.

Phase 3

05 Jun 2024

·www.drugs.com

First Patient Enrolled in Global Phase 3 Clinical Program for Elamipretide in Patients with Dry Age-Related Macular Degeneration

NEEDHAM, Mass., June 05, 2024. Stealth BioTherapeutics Inc. (the "Company" or "Stealth"), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that it has enrolled and dosed its first patient in the ReNEW trial (NCT06373731) as part of its Phase 3 clinical program for elamipretide in patients with dry age-related macular degeneration (dry AMD). The program consists of the two Phase 3 trials, ReNEW and ReGAIN. Both trials will evaluate the efficacy, safety, and pharmacokinetics of daily subcutaneous injections of elamipretide in participants with dry AMD. The primary efficacy endpoint will measure the rate of change in the macular area of photoreceptor loss, assessed by spectral domain-optical coherence tomography (SD-OCT) and ellipsoid zone (EZ) mapping at week 48. "Enrolling the first patient in our Phase 3 program puts us one step closer to bringing a potential first-in-class, at-home treatment option to patients living with dry AMD," said Reenie McCarthy, Chief Executive Officer. "With multiple sites now active and able to enroll patients in the U.S., we are off to a great start and look forward to evaluating the efficacy and safety of elamipretide in patients with dry AMD in these pivotal Phase 3 trials." "There remains a tremendous need for new therapies with differentiated mechanisms of action to treat dry AMD, especially those that could be readily employed for the management of earlier stages of disease," said Charles Wykoff, MD, PhD from Retinal Consultants of Texas. "Elamipretide, a mitochondrial targeted therapy, can be self-administered by patients at home. It holds the potential to be a transformative approach to dry AMD management by targeting the bioenergetic imbalance implicated in the progressive loss of photoreceptors that defines AMD and leads to progressive visual decline." About ReNEW and ReGAIN ReNEW and ReGAIN are Phase 3 global clinical trials evaluating the efficacy and safety of once-daily subcutaneous injections of elamipretide in participants with dry AMD. The primary endpoint for the trials is the rate of change in the macular area of photoreceptor loss assessed by spectral domain-optical coherence tomography and ellipsoid zone mapping. In the ReNEW trial, 360 patients will be randomized 2:1 to either elamipretide or placebo for 96 weeks with the option for participants to enroll in the open-label extension trial, ReTAIN. About dry AMD AMD is the leading cause of irreversible blindness and is estimated by the Vision and Eye Health Surveillance System to affect 19.8 million Americans aged 40 and older (Rein 2022), with 85% to 90% of cases being dry AMD (Schultz 2021). Dry AMD is a progressive retinal disease in which the photoreceptors, which are specialized neurons found in the retina that convert light into electrical signals required for normal visual function, suffer progressive damage and death, leading to loss of vision. Mitochondrial dysfunction, which has been associated with aging, smoking, obesity, and cardiovascular health, is known to precede clinical symptoms of AMD and increase commensurate with AMD disease progression (Feher 2006; Karunadharma 2010; Terluk 2015). Photoreceptor loss can be quantified by measuring the thickness between the EZ and retinal pigment epithelium (i.e., EZ-RPE thickness). Loss of photoreceptors cells, or EZ attenuation, has been shown to precede and predict the loss of visual function and areas of geographic atrophy in dry AMD. About Stealth BioTherapeutics Stealth BioTherapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for age-related and rare genetic diseases involving mitochondrial dysfunction. The Company is initiating Phase 3 clinical trials of elamipretide, its lead investigational product candidate, in dry age-related macular degeneration. Elamipretide is also being tested in a fully enrolled Phase 3 clinical trial in primary mitochondrial myopathy, a rare skeletal myopathic disease, and is under review by the Food and Drug Administration for Barth syndrome, an ultra-rare cardioskeletal disease. The Company is developing its second-generation clinical-stage candidate, bevemipretide (SBT-272), for ophthalmic and neurological disease indications. The Company has a deep pipeline of novel mitochondria-targeted compounds under evaluation as therapeutic product candidates. SOURCE Stealth BioTherapeutics Inc. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

Phase 3

07 May 2024

·www.prnewswire.com

STEALTH BIOTHERAPEUTICS' BARTH SYNDROME NDA RECEIVES PRIORITY REVIEW DESIGNATION

Barth Syndrome is an Ultra-rare, Progressive, Life-Shortening, Cardioskeletal Disease that Affects Approximately 150 Individuals in the United States If Approved, Elamipretide Would Become the First Approved Therapy for Barth Syndrome NEEDHAM, Mass., May 7, 2024 /PRNewswire/ -- Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the U.S. Food and Drug Administration ("FDA") has now determined that its New Drug Application ("NDA") for elamipretide for the treatment of Barth syndrome is entitled to a Priority Review designation. Per FDA policy, the user fee goal date of January 29, 2025 is unchanged. The FDA grants Priority Review to applications for therapies that have the potential to provide significant improvements in the treatment, diagnosis, or prevention of serious conditions. Barth syndrome is an ultra-rare cardioskeletal disease which results in frequent pediatric deaths and imposes a significant disease burden on all affected individuals. There are no other therapies approved or known to be in clinical development for this disease. The FDA's decision to grant Priority Review designation follows its March 29, 2024 filing decision in which the FDA assigned a standard review designation. Elamipretide has previously received Orphan Drug, Fast Track and Rare Pediatric Designations for elamipretide for the treatment of Barth syndrome. "We are pleased that the FDA has recognized the serious nature of Barth syndrome, the urgency of the unmet medical need, and the potential for elamipretide, if approved, to significantly improve treatment of this devastating disease," said Reenie McCarthy, Chief Executive Officer. "We welcome our continued constructive engagement with the Agency as we complete the review process and plan for an anticipated advisory committee meeting later this year." If approved, this would be the first marketing authorization for elamipretide, a first-in-class mitochondrial targeted therapeutic. Elamipretide is also in development for primary mitochondrial myopathy, with pivotal data from the fully-enrolled Phase 3 NuPOWER trial expected in late 2024, and dry age-related macular degeneration, with pivotal Phase 3 clinical trials initiating this quarter. About Barth Syndrome Barth syndrome is an ultra-rare genetic condition characterized by cardiac abnormalities leading to exercise intolerance, muscle weakness, debilitating fatigue, heart failure, recurrent infections, and delayed growth. The disease is associated with reduced life expectancy, with 85% of early deaths occurring by age 5. Barth syndrome occurs almost exclusively in males and is estimated to affect one in 1,000,000 males worldwide or around 150 individuals in the United States. There are currently no FDA- or EMA-approved therapies for patients with Barth syndrome. Elamipretide has Orphan Drug, Fast Track and Rare Pediatric Designation from the FDA and Orphan Drug Designation from the EMA for the treatment of Barth syndrome. About Stealth BioTherapeutics Stealth BioTherapeutics is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction. Mitochondria, found in nearly every cell in the body, are the body's main source of energy production and are critical for normal organ function. Dysfunctional mitochondria characterize a number of rare genetic diseases and are involved in many common age-related diseases, typically involving organ systems with high energy demands such as the heart, the eye, and the brain. The Company believes its lead product candidate, elamipretide, has the potential to treat rare diseases including Barth syndrome and primary mitochondrial myopathy and common age-related diseases including dry age-related macular degeneration. The Company is also evaluating a topical ophthalmic formulation of its second-generation clinical-stage candidate, SBT-272, for dry age-related macular degeneration. The Company has a deep pipeline of novel compounds under evaluation for rare neurological and cardiac disease indications following promising preclinical data. Media Contact Anna Stallmann Communications Anna Stallmann [email protected] Investor Relations Contact Austin Murtagh Stern Investor Relations [email protected] SOURCE Stealth BioTherapeutics Inc.

Priority ReviewFast TrackOrphan DrugNDAPhase 3

100 Deals associated with Elamipretide Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D10925	-	-	DB11981

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Barth Syndrome	NDA/BLA	US	Stealth BioTherapeutics, Inc.	08 Apr 2024
dry age-related macular degeneration	Phase 3	US	Stealth BioTherapeutics, Inc.	30 May 2024
Mitochondrial Complex I Deficiency	Phase 3	US	Stealth BioTherapeutics, Inc.	29 Apr 2022
Mitochondrial Complex I Deficiency	Phase 3	AU	Stealth BioTherapeutics, Inc.	29 Apr 2022
Mitochondrial Complex I Deficiency	Phase 3	DE	Stealth BioTherapeutics, Inc.	29 Apr 2022
Mitochondrial Complex I Deficiency	Phase 3	HU	Stealth BioTherapeutics, Inc.	29 Apr 2022
Mitochondrial Complex I Deficiency	Phase 3	IT	Stealth BioTherapeutics, Inc.	29 Apr 2022
Mitochondrial Complex I Deficiency	Phase 3	NL	Stealth BioTherapeutics, Inc.	29 Apr 2022
Mitochondrial Complex I Deficiency	Phase 3	NZ	Stealth BioTherapeutics, Inc.	29 Apr 2022
Mitochondrial Complex I Deficiency	Phase 3	NO	Stealth BioTherapeutics, Inc.	29 Apr 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03891875 (RECLAIM-2, CTgov)	Phase 2	Age Related Macular Degeneration \| Geographic Atrophy \| Glycogen Storage Disease Type II	176	Subcutaneous elamipretide through the elamipretide delivery system (Elamipretide)	pfwgzgqgjc(cipisimiwq) = elfrmfzdlf fxgroeoikv (jezlgfedbk, xzxmryhheg - snhheqonzy) View more	-	17 Oct 2023
				Subcutaneos placebo through the elamipretide delivery system (Placebo)	pfwgzgqgjc(cipisimiwq) = tcbmigoauk fxgroeoikv (jezlgfedbk, tsmgmtatpq - qsndznnebj) View more
NCT03323749 (MMPOWER-3, Pubmed)	Phase 3	Mitochondrial Myopathies	218	Elamipretide 40mg/day	zagzljtdql(hjrbnilakc) = rurndyrqcn fafeluecza (bvvrgsqsed )	Negative	02 Jun 2023
ARVO2023	Phase 2	Geographic Atrophy	117	Elamipretide 40 mg once daily	aasibbdzus(xpyulftrmj) = cmnovpbajd taextcuemn (tcvvuqdjdk ) View more	-	23 Apr 2023
				Placebo	aasibbdzus(xpyulftrmj) = ianbhyfrbt taextcuemn (tcvvuqdjdk ) View more
NCT03891875 (RECLAIM-2, PRNewswire) Manual	Phase 2	Geographic Atrophy	176	ELAMIPRETIDE	fjdzciqvtd(nstkwmvgwt) = tbradulusa npdgrmjrqz (ecdtsigick )	Positive	02 May 2022
				Placebo	-
ReCLAIM-1 (AAO2021)	Phase 1	Geographic Atrophy	-	Elamipretide 40mg	xrbjkuxhqi(tgskqkzspt) = rwsmxiofcx rizwgmxdyz (ibffjpyhzr ) View more	-	13 Nov 2021
NCT03098797 (Pubmed \| Genet Med) Manual	Phase 2/3	Barth Syndrome	12	elamipretide	rwnrziyjbb(outhloqwsa) = pylvqmftra yujvypzvtg (stwwnyhuso ) View more	Positive	01 Mar 2021
NCT01755858 (EVOLVE, CTgov)	Phase 1/2	Hypertension, Renovascular \| Renal Artery Obstruction \| Reperfusion Injury	16	Bendavia (Bendavia)	ssrpbbtyqg(jdhcyyispq) = ifchstufgt yvinvzmzdg (lmqxlvtvmk, ybdnoohevd - utqfpanllu) View more	-	11 Aug 2020
				Placebo (Placebo)	ssrpbbtyqg(jdhcyyispq) = hdsqrdaolx yvinvzmzdg (lmqxlvtvmk, nqegmpcesr - nnqyjhmqzz) View more
NCT02805790 (Pubmed) Manual	Phase 2	Mitochondrial Myopathies	30	elamipretide	filsrtcfyk(vjjfhqxrdo) = ocjohvujaw ozkmyaytdv (umhsxlzkag, 134.16)	Positive	01 Aug 2020
				Placebo	filsrtcfyk(vjjfhqxrdo) = rxsqyitaeq ozkmyaytdv (umhsxlzkag, 125.10)
NCT02245620 (CTgov)	Phase 2	Muscular Diseases	41	Placebo (Placebo)	olvcfiqswu(ycivswecsz) = fizdvxydhq clmoizdfih (tdivdczjvz, ewkboqxkxy - rsjzfanmzf) View more	-	23 Jun 2020
				Elamipretide (Elamipretide)	wzhrcmqdei(ewyyfqkioh) = weohsaljad uagtaaqyrb (zblmtmchvb, nqiutmjfij - gvdqrfjljz) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis